Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Patients With Advanced Non–Small Cell Lung Cancer
In a large, real-world cohort of advanced NSCLC patients tested with CGP, the treatment adherence rate to matched NCCN-recommended targeted therapy was high. This study highlights the importance of CGP testing in identifying variants to provide timely matched targeted therapy in a rapidly evolving biomarker and therapeutic landscape.
Authors
- Luis E. Raez (ORCID: https://orcid.org/0000-0003-2669-5771)
- Rotem Ben‐Shachar (ORCID: https://orcid.org/0000-0002-2717-0259)
- Ira Klein (ORCID: https://orcid.org/0000-0002-5959-0557)
- Daniel Morgensztern (ORCID: https://orcid.org/0000-0003-4349-2028)
- Halla Nimeiri (ORCID: https://orcid.org/0000-0002-8760-6456)
- Mark Carty
- Akash Mitra (ORCID: https://orcid.org/0000-0002-0633-1615)
- Kaveri Nadhamuni
- R. Pelossof
Institutions
- Washington University in St. Louis (US)
- Memorial Healthcare System (US)
- Tempus Labs (United States) (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1200/op-24-00880
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00